Grufity logo
Grufity logo
KRON

KRON - Kronos Bio Inc Stock Price, Fair Value and News

$5.95 
Market Closed as of 07 Nov 2025, 04:00 pm ET

Price Targets

KRON Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

KRON Price Action

Last 7 days

-0.7%

Last 30 days

-0.2%

Last 90 days

2.1%

Trailing 12 Months

13.1%

KRON RSI Chart

KRON Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

KRON Valuation

Market Cap

362.8M

Price/Earnings (Trailing)

-4.21

Price/Sales (Trailing)

36.84

Price/Free Cashflow

-5.54

KRON Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

KRON Fundamentals

KRON Revenue

KRON Earnings

KRON Profitability

Free Cashflow Yield

-18.04%

KRON Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2025----
20247.6M8.4M-9.8M
2023---6.3M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Kronos Bio Inc

KRON
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial; and Lanraplenib, a next-generation SYK inhibitor to treat the patients with relapsed/refractory FLT3-mutated acute myeloid leukemia. The company was incorporated in 2017 and is headquartered in San Mateo, California.
 CEO
 WEBSITEhttps://kronosbio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES104

Kronos Bio Inc Frequently Asked Questions

KRON is the stock ticker symbol of Kronos Bio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Nov 07 2025, market cap of Kronos Bio Inc is 362.77 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Nov 07 2025, KRON's PE ratio (Price to Earnings) is -4.21 and Price to Sales (PS) ratio is 36.84. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KRON PE ratio will change depending on the future growth rate expectations of investors.